CRISPR/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer.

Ailin ChenShijun WenFang LiuZijian ZhangMeiling LiuYuanzhong WuBin HeMin YanTiebang KangEric W-F LamZi-Feng Wang Quentin Liu

Published in: Cancer communications (London, England) (2021)

These findings establish Haspin as a synthetic lethal target and demonstrate CHR-6494 as a potential combinational drug for promoting the therapeutic effects of MLN8237 on breast cancer.

Keyphrases

crispr cas
genome editing
genome wide
risk assessment
drug induced
electronic health record